ABSTRACT
Background Since partial oxygen pressure decreases as altitude increases, environmental hypoxia could worsen COVID-19 patient’s hypoxemia. We compared COVID-19 mortality at different altitudes.
Methods Retrospective analysis of population-level data on COVID-19 deaths in the U.S. (1,016 counties) and Mexico (567 municipalities). Mixed-model Poisson regression analysis of the association between altitude and COVID-19 mortality using individual-level data from 40,168 Mexican subjects with COVID-19, adjusting for multiple covariates.
Results Between January 20 and April 13, 2020, mortality rates were higher in U.S. counties located at ≥2,000 m elevation vs. those located below 1,500 m (12.3 vs. 3.2 per 100,000; P<0.001). In Mexico, between March 13 and May 13, 2020, mortality rates were higher in municipalities located at ≥2,000 m vs. <1,500 m (5.3 vs. 3.9 per 100,000; P<0.001). Among Mexican subjects <65 years old, the risk of death was 36% higher in those living at ≥2,000 m vs. <1,500 m (adjusted incidence rate ratio: 1.36; 95% CI, 1.05-1.78; P=0.022). Among men, the risk of death was 31% higher at ≥2,000 m vs. <1,500 m (adjusted IRR: 1.31; 95% CI, 1.03-1.66; P=0.025). No association was found among women.
Conclusion Altitude is associated with COVID-19 mortality in men younger than 65 years.
Competing Interest Statement
OOW has nothing to disclose. RNB received grants from the NIH (DK7619 and DK29867).
Funding Statement
Sources of Support: Self-funded
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study did not require approval or exemption from the Cedars-Sinai Medical Center Institutional Review Board as it involved the analysis of publicly available de-identified data only.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Sources of Support: Self-funded
AUTHORSHIP CONFIRMATION STATEMENT OOW: study design, data collection, statistical analyses, data interpretation, final draft writing.
RNB: study design, data interpretation, final draft writing. OOW and RNB have reviewed and approved the manuscript prior to submission.
AUTHOR DISCLOSURE STATEMENTS OOW has nothing to disclose. RNB received grants from the NIH (DK7619 and DK29867).
Data Availability
All data are publicly available online.
